Cleared Traditional

ANTI-MUTATED CITRULLINATED VIMENTIN EIA (K092399) - FDA 510(k) Clearance

Class II Immunology device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K092399 · Orgentec Diagnostika GmbH · Immunology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jul 2010
Decision
329d
Days
Class 2
Risk

K092399 is an FDA 510(k) clearance for the ANTI-MUTATED CITRULLINATED VIMENTIN EIA. Classified as Anti-mutated Citrullinated Vimentin Igg (product code OQZ), Class II - Special Controls.

Submitted by Orgentec Diagnostika GmbH (East Stroudsburg, US). The FDA issued a Cleared decision on July 1, 2010 after a review of 329 days - an unusually long review period, suggesting complex equivalence evaluation.

This device falls under the Immunology FDA review panel, regulated under 21 CFR 866.5775 - the FDA immunology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Elevated predicate reliance profile. This clearance follows a standard predicate-based equivalence path within the Immunology review framework, consistent with the majority of Class II 510(k) submissions.

View all Orgentec Diagnostika GmbH devices

Submission Details

510(k) Number K092399 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received August 06, 2009
Decision Date July 01, 2010
Days to Decision 329 days
Submission Type Traditional
Review Panel Immunology (IM)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
225d slower than avg
Panel avg: 104d · This submission: 329d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code OQZ Anti-mutated Citrullinated Vimentin Igg
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.5775
Definition For The Semi-quantitative Measurement Of Igg Class Autoantibodies Against Mutated Citrullinated Vimentin (mcv) In Human Serum Or Plasma.
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Immunology devices follow this clearance model.